

Drug Lists for Review by the PDAB

- ▶ Minn. Stat. § 62J.90 Subd. 2 Drugs
- ▶ PDAB Listening Session Drugs
- ▶ Medicare Maximum Fair Price Drugs

Minn. Stat. § 62J.90 Subd. 2 Drugs

- ▶ List produced by MDH based on statutory criteria
- ▶ Over 1200 NDCs
- ▶ ~ 320 Drugs

Minn. Stat. § 62J.90 Criteria

62J.90 PRESCRIPTION DRUG PRICE INFORMATION; DECISION TO CONDUCT COST REVIEW.

Subdivision 1. Drug price information from the commissioner of health and other sources.

- (a) The commissioner of health shall provide to the board the information reported to the commissioner by drug manufacturers under section [62J.84](#), [subdivisions 3](#), 4, and 5. The commissioner shall provide this information to the board within 30 days of the date the information is received from drug manufacturers.
- (b) The board may subscribe to one or more prescription drug pricing files, such as Medispan or FirstDatabank, or as otherwise determined by the board.

Minn. Stat. § 62J.90 Criteria

62J.90 PRESCRIPTION DRUG PRICE INFORMATION; DECISION TO CONDUCT COST REVIEW.

Subd. 2. Identification of certain prescription drug products.

(a) The board, in consultation with the advisory council, shall identify selected prescription drug products based on the following criteria:

- (1) brand name drugs or biologics for which the WAC increases by more than 15 percent or by more than \$3,000 during any 12-month period or course of treatment if less than 12 months, after adjusting for changes in the consumer price index (CPI);
- (2) brand name drugs or biologics with a WAC of \$60,000 or more per calendar year or per course of treatment;
- (3) biosimilar drugs that have a WAC that is not at least 20 percent lower than the referenced brand name biologic at the time the biosimilar is introduced; and
- (4) generic drugs for which the WAC:
 - (i) is \$100 or more, after adjusting for changes in the CPI, for:
 - (A) a 30-day supply;
 - (B) a course of treatment lasting less than 30 days; or
 - (C) one unit of the drug, if the labeling approved by the Food and Drug Administration does not recommend a finite dosage; and
 - (ii) increased by 200 percent or more during the immediate preceding 12-month period, as determined by the difference between the resulting WAC and the average WAC reported over the preceding 12 months, after adjusting for changes in the CPI.

The board is not required to identify all prescription drug products that meet the criteria in this paragraph.

Minn. Stat. § 62J.90 Criteria

62J.90 PRESCRIPTION DRUG PRICE INFORMATION; DECISION TO CONDUCT COST REVIEW.

Subd. 2. Identification of certain prescription drug products.

(b) The board, in consultation with the advisory council and the commissioner of health, may identify prescription drug products not described in paragraph (a) that may impose costs that create significant affordability challenges for the state health care system or for patients, including but not limited to drugs to address public health emergencies.

Minn. Stat. § 62J.90 Implementation

62J.92 DETERMINATIONS; COMPLIANCE; REMEDIES.

* * *

Subd. 2. Implementation and administration of the upper payment limit.

* * *

(b) When setting an upper payment limit for a drug subject to the Medicare maximum fair price under United States Code, title 42, section 1191(c), the board shall set the upper payment limit at the Medicare maximum fair price.

PDAB Listening Session Drugs

- ▶ GLP-1s (Ozempic, Wegovy)
- ▶ Albuterol inhalers
- ▶ COPD inhalers
- ▶ MS medications
- ▶ Insulin/Diabetes Medications
- ▶ HIV long acting injectables
- ▶ Cromolyn Sodium (mastocytosis)
- ▶ SUNOSI (narcolepsy)
- ▶ XYWAV (narcolepsy, cataplexy)
- ▶ Eliquis (anticoagulant)
- ▶ Repatha (PCSK9 inhibitor)

Medicare Maximum Fair Price Drugs

- ▶ Ten Drugs effective 2026
- ▶ Fifteen Drugs effective 2027
- ▶ Fifteen Drugs effective 2028 (MFP established by Nov. 2026)
- ▶ Selection Criteria
 - ▶ Single-source brand-name medication or biological products
 - ▶ Duration on the market: At least seven years for small-molecule drugs, eleven years for biological products
 - ▶ High total gross covered prescription drug costs
 - ▶ Low-spend drugs or orphan drugs designated for only one rare disease excluded from selection process.
- ▶ Negotiated discounts range from 38% - 79%

2026 Medicare Maximum Fair Price Drugs

Drug	Januvia	Flasp	Farxiga	Enbrel	Jardiance
Manufacturer	Merck Sharp Dohme	Novo Nordisk Inc	AstraZeneca AB	Immunex Corporation	Boehringer Ingelheim
Conditions	Diabetes	Diabetes	Diabetes; Heart failure; Chronic kidney disease	Rheumatoid arthritis; Psoriasis; Psoriatic arthritis	Diabetes; Heart failure; Chronic kidney disease
Negotiated Price '26	\$113	\$119	\$178	\$2,355	\$197
List Price '23	\$527	\$495	\$556	\$7,106	\$573
Discount	79%	76%	68%	67%	56%

2026 Medicare Maximum Fair Price Drugs

Drug	Stelara	Xarelto	Eliquis	Entresto	Imbruvica
Manufacturer	Janssen Biotech, Inc	Janssen Pharms	Bristol Myers Squibb	Novartis Pharms Corp	Pharmacyclics LL
Conditions	Psoriasis; Psoriatic arthritis; Crohn's disease; Ulcerative colitis	Prevention and treatment of blood clots; Reduction of risk for coronary or peripheral artery disease	Prevention and treatment of blood clots	Heart failure	Blood cancers
Negotiated Price '26	\$4,695	\$197	\$231	\$295	\$9,319
List Price '23	\$13,836	\$517	\$521	\$628	\$14,934.00
Discount	66%	62%	56%	53%	38%

2027 Medicare Maximum Fair Price Drugs

Drug	Ozempic; Rybelsus; Wegovy	Trelegy Ellipta	Xtandi	Pomalyst	Ofev
Manufacturer	Novo Nordisk Inc	GlaxoSmithKline	Astellas Pharma US, Inc.	Bristol-Myers Squibb Co.	Boehringer Ingelheim Pharmaceuticals
Conditions	Type 2 Diabetes; Cardiovascular disease	Asthma; Chronic obstructive pulmonary disease	Prostate cancer	Kaposi sarcoma; Multiple myeloma	Idiopathic pulmonary fibrosis
Negotiated Price '27	\$275	\$175	\$7,004	\$8,650	\$6,350
List Price '24	\$959	\$654	\$13,480	\$21,744	\$12,622
Discount	71%	73%	48%	60%	50%

2027 Medicare Maximum Fair Price Drugs

Drug	Ibrance	Linzess	Calquence	Austudeo	Breo Elliptas
Manufacturer	Pfizer	AbbVie Inc.	AstraZeneca UK Limited	Teva Branded Pharmaceutical Products R&D LLC	GlaxoSmithKline Intellectual Property Development Ltd. England
Conditions	Breast Cancer	Chronic idiopathic constipation; Irritable bowel syndrome with constipation	Chronic lymphocytic leukemia/small lymphocytic lymphoma; Mantle cell lymphoma	Chorea in Huntington's disease; Tardive dyskinesia	Asthma; Chronic obstructive pulmonary disease
Negotiated Price '27	\$7,871	\$136	\$8,600	\$4,093	\$67
List Price '24	\$15,741	\$539	\$14,228	\$6,623	\$397
Discount	50%	75%	40%	38%	83%

2027 Medicare Maximum Fair Price Drugs

Drug	Manufacturer	Conditions	Negotiated Price '27	List Price '24	Discount
Xifaxen	Salix Pharmaceuticals Inc	Hepatic encephalopathy; Irritable bowel syndrome with diarrhea	\$1,000	\$2,696	63%
Vraylar	AbbVie Inc.	Bipolar I disorder; Major depressive disorder; Schizophrenia	\$770	\$1,376	44%
Tradjenta	Boehringer Ingelheim Pharmaceuticals, Inc.	Type 2 diabetes	\$78	\$488	84%
Janumet; Janumet XR	Merck Sharp & Dohme LLC	Type 2 diabetes	\$80	\$526	85%
Otzela; Otzela XR	Amgen Inc.	Oral ulcers in Behçet's Disease; Plaque psoriasis; Psoriatic arthritis	\$1,650	\$4722	65%

2028 Medicare Maximum Fair Price Drugs

Drug	Condition(s)
Trulicity	Type 2 diabetes; Type 2 diabetes and cardiovascular disease or multiple cardiovascular risk factors
Bictarvy	Human immunodeficiency virus type 1 infection
Orencia	Psoriatic arthritis; Rheumatoid arthritis
Cosentyx	Plaque psoriasis; Psoriatic arthritis
Erleada	Prostate cancer
Kisqali	Breast cancer
Entyvio	Crohn's disease; Ulcerative colitis

2028 Medicare Maximum Fair Price Drugs

Drug	Condition(s)
Verzenio	Breast cancer
Botox	Chronic migraine; Overactive bladder; Spasticity; Other movement disorders
Lenvima	Thyroid cancer; Endometrial cancer; Liver cancer; Kidney cancer
Xolair	Asthma; Chronic spontaneous urticaria
Rexulti	Major depressive disorder; Schizophrenia; Agitation associated with dementia due to Alzheimer's disease
Xeljanz	Psoriatic arthritis; Rheumatoid arthritis; Ulcerative colitis
Anoro Ellipta	Chronic obstructive pulmonary disease
Cimzia	Chron's disease; Plaque psoriasis; Psoriatic arthritis; Rheumatoid arthritis